Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors. - Wikidata - awgldk - TriplyDB

Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.

Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.

http://www.wikidata.org/entity/Q39418429

about

Targeting of erbB3 receptor to overcome resistance in cancer treatment Regulation of ERBB3/HER3 signaling in cancer Quantitative optical imaging of primary tumor organoid metabolism predicts drug response in breast cancer.miR-143 and miR-145 synergistically regulate ERBB3 to suppress cell proliferation and invasion in breast cancer.miR-193a-3p functions as a tumor suppressor in lung cancer by down-regulating ERBB4.Preexisting oncogenic events impact trastuzumab sensitivity in ERBB2-amplified gastroesophageal adenocarcinoma Decreased LRIG1 in fulvestrant-treated luminal breast cancer cells permits ErbB3 upregulation and increased growth.Anti-HER3 domain 1 and 3 antibodies reduce tumor growth by hindering HER2/HER3 dimerization and AKT-induced MDM2, XIAP, and FoxO1 phosphorylation.Synergistic antitumor activity of histone deacetylase inhibitors and anti-ErbB3 antibody in NSCLC primary cultures via modulation of ErbB receptors expression.Challenges and advances in mouse modeling for human pancreatic tumorigenesis and metastasis The promise of anti-ErbB3 monoclonals as new cancer therapeutics Emerging anti-cancer antibodies and combination therapies targeting HER3/ERBB3.Combination of antibodies directed against different ErbB3 surface epitopes prevents the establishment of resistance to BRAF/MEK inhibitors in melanoma.Anti-HER3 Monoclonal Antibody Inhibits Acquired Trastuzumab-Resistant Gynecologic Cancers.Targeting HER3 using mono- and bispecific antibodies or alternative scaffolds.Combination therapy with anti-ErbB3 monoclonal antibodies and EGFR TKIs potently inhibits non-small cell lung cancer Activation of an early feedback survival loop involving phospho-ErbB3 is a general response of melanoma cells to RAF/MEK inhibition and is abrogated by anti-ErbB3 antibodies.Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib Meta-analysis reveals no significant correlation between breast cancer survival and ErbB3 expression.Irreversible tyrosine kinase inhibition of epidermal growth factor receptor with afatinib in EGFR activating mutation-positive advanced non-small-cell lung cancer.

P2860

Q26864668-D80281E6-CAE3-4E56-A6D0-52688D999022 Q27024334-023A57D9-AC2C-4799-9863-B5AD0D8EC3CA Q34205196-D887D46F-0DBB-4F79-AF60-1EEF8F2CC8B3 Q34273176-CDFB13FD-257F-4A26-9012-7ED6BD551B9A Q34958888-607F8651-EDB6-413B-B854-EEC94FB83DD6 Q35145369-78092E76-5E2B-4192-B60C-B3FCEAA1AADA Q36437261-FDFE172B-DC1F-4135-8637-A86D258B5F54 Q36670915-AEBA071C-6B4B-4A6C-B83F-535D743EE0BF Q37190106-262D2141-E283-467D-98A0-E18A89A2E735 Q37411831-8E0DC155-6340-4016-AE61-178AC92C73C7 Q38034347-4BFBC0C3-7C81-48EB-88B7-64E1A4D049DB Q38623361-0F0C78A0-11FC-4C59-A713-4AE80D106373 Q38849622-EC763CE9-79E3-4426-A8EF-FD3F6AFA6847 Q38867798-D4DDD602-E0FD-4F95-BDEC-EAC95D091CC3 Q38929801-44D466FD-04A5-4AEB-A2D1-48F5EE10A160 Q39118597-77ABE851-9E95-4D68-AF5B-A8EBA316497F Q39119920-9EF4EA65-CAE1-4E17-8019-14F0FBC60F19 Q39339545-7F3D3261-050D-4E07-BE41-6C88A5EE3E11 Q55060477-E736928A-911B-47C9-8234-3699B09484F6 Q55224621-4777E2A2-F638-41B2-94EB-E9E3B94269BC

P2860

Novel anti-ErbB3 monoclonal antibodies show therapeutic efficacy in xenografted and spontaneous mouse tumors.

http://www.wikidata.org/entity/Q39418429

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Novel anti-ErbB3 monoclonal an ...... and spontaneous mouse tumors.

@en

Novel anti-ErbB3 monoclonal an ...... and spontaneous mouse tumors.

@nl

type

label

Novel anti-ErbB3 monoclonal an ...... and spontaneous mouse tumors.

@en

Novel anti-ErbB3 monoclonal an ...... and spontaneous mouse tumors.

@nl

prefLabel

Novel anti-ErbB3 monoclonal an ...... and spontaneous mouse tumors.

@en

Novel anti-ErbB3 monoclonal an ...... and spontaneous mouse tumors.

@nl

P1433

Q39418429-B8AFAE1C-1D49-4C5C-998B-FCD0CF7C0F4A

P1476

Q39418429-D12852C4-4572-41EF-A70E-FF817FF9D002

P2093

Q39418429-2A2F88C9-3491-4BE6-9B37-49DC2F10CE95

Q39418429-2B4443FC-0752-42B7-AE8C-841667114A6B

Q39418429-3162A342-305B-431F-B1DF-B49F56F3B6A5

Q39418429-3B4B373A-0EDE-4E4D-8F86-775E54F8CD80

Q39418429-54BEF303-D557-4FFC-B8F8-AFCAF031DE68

Q39418429-6BECC508-F45D-42D6-8E32-6A3D68A67877

Q39418429-707C9E6F-E1EC-459B-9582-520D074307D9

Q39418429-8C0DF3BB-B31A-4D16-BC76-E45B47BF424D

Q39418429-9C6D14AC-7DF6-4368-AB77-2ECED79EC490

Q39418429-BF3FDC16-1C3C-4F42-96E3-86F49917A709

P2860

Q39418429-05AB1F41-18C0-4F56-A1B6-719E9B832D9B

Q39418429-1028419D-89E0-47EA-8DCE-3B635CC53795

Q39418429-14464787-3FF1-4979-B38A-31D810264BBC

Q39418429-1E7DFA5B-5DDE-450B-BBFD-4A1B3D3859D2

Q39418429-26B246ED-436B-4B01-9EBF-10C52E77F3EC

Q39418429-2958606B-0527-4F98-92A7-E51DE1306FFA

Q39418429-3818AC99-E0D0-4E8B-85AE-F5A32D1BC0B5

Q39418429-3C2A2215-54D5-41CC-9BAB-CA9458FECD5D

Q39418429-412C054C-74CB-4DB3-B729-7358027B2C28

Q39418429-4637D1DB-EE85-4A6F-ABE7-CAAD0BAF5A84

P304

Q39418429-3C7665CF-9FB6-41E4-A217-0192F031E467

P31

Q39418429-14E2842B-3594-4CC3-A358-7BE6F39255E5

P356

Q39418429-FCC81BFF-8631-414B-A9AA-6FF026022BB1

P433

Q39418429-3B8F522D-D3F1-426F-AF04-0D52FED7A7EA

P478

Q39418429-27C8E425-5F45-4ECB-9659-417EFABF6862

P50

Q39418429-A48E536F-EF12-4DB9-B695-DAA500ABE515

P577

Q39418429-72DBA28C-D3B8-4D6A-A673-62F79F829D0F

P5875

Q39418429-1560B096-06A9-4DBA-B278-419A6480F6BD

P698

Q39418429-8ABA6253-E283-45D7-A755-B3E37B64C373

P921

Q39418429-BC6CEABA-5CC2-43E9-A543-7B8142D1FCDB

P356

P1433

Journal of Cellular Physiology

P1476

Novel anti-ErbB3 monoclonal an ...... and spontaneous mouse tumors.

@en

P2093

Alessia Noto

http://www.w3.org/2001/XMLSchema#string

Claudia De Vitis

http://www.w3.org/2001/XMLSchema#string

Emanuele Marra

http://www.w3.org/2001/XMLSchema#string

Fabrizio Carlomosti

http://www.w3.org/2001/XMLSchema#string

Giuseppe Mesiti

http://www.w3.org/2001/XMLSchema#string

Giuseppe Roscilli

http://www.w3.org/2001/XMLSchema#string

Laura Luberto

http://www.w3.org/2001/XMLSchema#string

Luigi Aurisicchio

http://www.w3.org/2001/XMLSchema#string

Maurizio Alimandi

http://www.w3.org/2001/XMLSchema#string

Rita Mancini

http://www.w3.org/2001/XMLSchema#string

P2860

PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer

Epidermal growth factor and betacellulin mediate signal transduction through co-expressed ErbB2 and ErbB3 receptors

Cell signaling by receptor tyrosine kinases

Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3

The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations

The ErbB2/ErbB3 heterodimer functions as an oncogenic unit: ErbB2 requires ErbB3 to drive breast tumor cell proliferation

ErbB receptors: from oncogenes to targeted cancer therapies

Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

P304

3381-3388

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/JCP.24037

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

227

http://www.w3.org/2001/XMLSchema#string

P50

Gennaro Ciliberto

P577

2012-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51976465

http://www.w3.org/2001/XMLSchema#string

P698

22213458

http://www.w3.org/2001/XMLSchema#string

P921